| In millions, except per share items | Jun-30-17 | Mar-31-17 | Dec-31-16 | Sep-30-16 | Jun-30-16 | Mar-31-16 | Dec-31-15 | Sep-30-15 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues: |
| U.S. Medical | 236.0 | 230.7 | 225.3 | 220.9 | 215.8 | 211.1 | 206.7 | 204.4 |
| International Medical | 48.6 | 46.9 | 45.5 | 43.2 | 41.7 | 40.4 | 39.3 | 39.3 |
| Total revenues | 284.6 | 277.6 | 270.8 | 264.1 | 257.5 | 251.4 | 246.0 | 243.7 |
| Revenue growth [+] | 10.5% | 10.4% | 10.1% | 8.4% | 6.9% | 12.9% | 20.0% | 32.5% |
| U.S. Medical | 9.4% | 9.3% | 9.0% | 8.0% | 7.4% | 14.6% | 23.5% | 36.7% |
| International Medical | 16.6% | 16.2% | 15.9% | 10.0% | 4.5% | 4.8% | 4.7% | 14.5% |
| Cost of goods sold | 71.8 | 70.3 | 68.3 | 66.1 | 65.0 | 63.9 | 62.6 | 62.4 |
| Gross profit | 212.8 | 207.3 | 202.5 | 198.0 | 192.5 | 187.5 | 183.3 | 181.3 |
| Gross margin | 74.8% | 74.7% | 74.8% | 75.0% | 74.8% | 74.6% | 74.5% | 74.4% |
| Selling, general and administrative [+] | 174.1 | 169.2 | 164.3 | 158.9 | 152.3 | 147.2 | 143.4 | 143.1 |
| Sales and marketing | 131.9 | 127.0 | | 122.2 | 115.5 | 110.5 | | 106.6 |
| General and administrative | | | 42.1 | | | | 36.7 | |
| Other operating expenses | 82.9 | 81.1 | 79.9 | 77.7 | 74.2 | 57.7 | 58.5 | 56.3 |
| EBITDA [+] | -10.1 | -15.5 | -14.3 | -11.0 | -6.5 | 10.0 | 8.0 | 7.5 |
| EBITDA growth | 55.5% | -255.3% | -278.0% | -247.6% | -190.8% | -309.8% | 522.7% | -15.7% |
| EBITDA margin | -3.6% | -5.6% | -5.3% | -4.2% | -2.5% | 4.0% | 3.3% | 3.1% |
| Depreciation | 19.5 | 15.4 | 15.2 | 15.0 | 14.6 | 14.0 | 13.3 | 12.5 |
| EBITA | -29.6 | -30.9 | -29.5 | -26.0 | -21.1 | -4.0 | -5.3 | -5.0 |
| EBITA margin | -10.4% | -11.1% | -10.9% | -9.8% | -8.2% | -1.6% | -2.1% | -2.0% |
| Amortization of intangibles | 14.6 | 11.9 | 12.2 | 12.5 | 12.9 | 13.3 | 13.3 | 13.1 |
| EBIT [+] | -44.2 | -42.9 | -41.7 | -38.5 | -34.0 | -17.4 | -18.6 | -18.1 |
| EBIT growth | 30.0% | 147.1% | 124.7% | 113.4% | 95.5% | -30.9% | 19.6% | 282.0% |
| EBIT margin | -15.5% | -15.4% | -15.4% | -14.6% | -13.2% | -6.9% | -7.5% | -7.4% |
| Non-recurring items [+] | 10.5 | 1.8 | 1.9 | 4.2 | 11.3 | 21.9 | 32.0 | 38.6 |
| Asset impairment | | | | | | | | 2.5 |
| Interest expense | 13.7 | 13.4 | 13.3 | 12.4 | 11.0 | 9.4 | 7.9 | 7.2 |
| Interest expense | 13.7 | 13.4 | 13.3 | 12.4 | 11.0 | 9.4 | 7.9 | 7.2 |
| Other income (expense), net [+] | 0.4 | -0.5 | -0.4 | -0.1 | -0.1 | 0.0 | -0.4 | -0.3 |
| Gain (loss) on foreign currency transactions | 0.4 | -0.5 | -0.4 | -0.1 | -0.1 | 0.0 | -0.4 | -0.3 |
| Change in value of contingent liability | | | | | | | -25.8 | -22.1 |
| Other | | | -7.1 | -5.9 | | | -8.2 | -7.5 |
| Pre-tax income | -68.0 | -58.5 | -57.3 | -55.2 | -56.3 | -48.7 | -58.7 | -64.2 |
| Income taxes | 1.0 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.7 | 0.8 |
| Net income | -69.1 | -59.4 | -58.1 | -56.0 | -57.2 | -49.5 | -59.5 | -65.0 |
| Net margin | -24.3% | -21.4% | -21.5% | -21.2% | -22.2% | -19.7% | -24.2% | -26.7% |
| |
| Basic EPS [+] | ($1.59) | ($1.38) | ($1.36) | ($1.31) | ($1.34) | ($1.16) | ($1.40) | ($1.54) |
| Growth | 18.9% | 18.5% | -3.4% | -15.0% | -12.6% | -22.2% | 42.8% | 162.5% |
| Diluted EPS [+] | ($1.59) | ($1.38) | ($1.36) | ($1.31) | ($1.34) | ($1.16) | ($1.40) | ($1.54) |
| Growth | 18.9% | 18.5% | -3.4% | -15.0% | -12.6% | -22.2% | 42.8% | 162.5% |
| |
| Shares outstanding (basic) [+] | 43.3 | 43.1 | 42.9 | 42.7 | 42.6 | 42.5 | 42.4 | 42.2 |
| Growth | 1.6% | 1.3% | 1.2% | 1.3% | 1.5% | 1.7% | 1.8% | 3.1% |
| Shares outstanding (diluted) [+] | 43.3 | 43.1 | 42.9 | 42.7 | 42.6 | 42.5 | 42.4 | 42.2 |
| Growth | 1.6% | 1.3% | 1.2% | 1.3% | 1.5% | 1.7% | 1.8% | 3.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |